Day 2, Tuesday, November 19, 2024 - ET (Eastern Time, GMT-05:00)
Day 2, Tuesday, November 19, 2024 - ET (Eastern Time, GMT-05:00)
- Chris Dowd - Senior Vice President, ConnectiveRx
National healthcare policy trends and legislative changes continue to be top-of-mind for many industry stakeholders in the access and reimbursement space.
- Deep dive into recent state regulations impacting 340B pricing, copay assistance and patient access to medications
- Discuss the proposed change by CMS to allow "stacking" of discounts and the respective implications on manufacturing distribution strategies and copay
- Outline the key provisions of the proposed transparency bill in Congress regarding copay assistance program
- Dissect key Medicare provisions and their impact on the copay ecosystem, including any nuances
- Delve into the establishment of inflation rebates for Part B and D drugs, including implications for pricing strategies and potential cost-sharing adjustments
- Analyze the annual out-of-pocket cap on Part D enrollee costs
- Discuss potential timelines and understand how to develop a comprehensive, compliant and financially sound strategy
- Michael Ziskind - Director, Public Policy, Strategy and Marketing, Johnson and Johnson (Invited)
Hear directly from U.S. attorneys on trends of upcoming areas of focus and enforcement for 2024 and beyond, specifically looking at guidance on field-based roles, prior authorization and other focal points.
- Daryl Kreml - Chief Enterprise Risk and Compliance Officer, Sage Therapeutics
- Steven Sharobem - Assistant United States Attorney, US Attorney’s Office, District of Massachusetts
- Charlene Fullmer - Assistant United States Attorney, US Attorney’s Office, Eastern District of Pennsylvania
In today’s complex landscape, the considerable financial burden of high-cost treatments presents ongoing barriers not only for patients, but also for pharmaceutical companies working to bring therapies to market. To effectively address these challenges, it’s crucial to adopt a customized affordability approach that considers the diverse needs of patients and the unique characteristics of drug classifications. Enhanced copay programs, supported by a comprehensive pharmacy network, play a vital role in improving patient access to necessary medications. In her session, Megan Wetzel, Sr. Director, Affordability Solutions at CoverMyMeds, will discuss ways to help ensure innovative affordability solutions are comprehensive and tailored to meet the specific needs through integrated actionable data, effective brand safeguards, and specialized expertise throughout the brand lifecycle.
- Megan Wetzel - Senior Director, Affordability Solutions, CoverMyMeds
Copay adjustment programs, encompassing maximizers, accumulators and optimizers, have become a complex landscape for patients, manufacturers and insurers. This session will dissect these programs, analyze their impact on stakeholders and explore strategies for manufacturers to ensure their copay support reaches patients as intended.
- Jennifer Murdock - Associate Director, South Atlantic, Field Reimbursement, Immunology, South Atlantic, Johnson & Johnson
Across the board, the healthcare industry has seen a shift in the overall money funnel and many companies are facing strict budget constraints. In turn, manufacturers are looking to invest later in their processes in order to derisk earlier. During this session, learn how to weigh the costs of innovation, ensuring that your organization remains dynamic, forward thinking and patient centric even amidst financial limitations.
- John Harlow - Chief Commercial Officer, Melinta Therapeutics
While not new, AI is undoubtedly here to stay. During this session, understand the various tools and AI applications that can be used to improve benefit verification and the ability of copay services.
- Recognize the advantages of AI to customize copay to patient need and streamline processes
- On the flip side, identify areas, such as patient hot lines, that potentially may not benefit from automation
- Identify new areas/skills/processes that AI can do that humans may not be able to
- Zoom out to see how AI impacts the total cost in healthcare, outside of standard research and development